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sTATE-OF-THE-ART PAPER1071Troponin Elevation in Patients With Heart Failureobb D. Kociol, Peter S. Pang, Mihai Gheorghiade, Gregg C. Fonarow, Christopher M. O’Connor,
. Michael Felker
atriuretic peptides have become increasingly important for the diagnosis and risk stratifi-
ation of patients with heart failure (HF). Many patients with HF also have detectable levels
f circulating cardiac troponin (cTn). Kociol and colleagues review the implications of
easuring and detecting cTn with the knowledge that more sensitive cTn assays are being
eveloped that can reliably quantify cTn at much lower levels. While the exact mechanism of
roponin release is unknown, research suggests that it may be related to myocyte necrosis,
poptosis, or cTn degradation or release in otherwise viable cells; each of these processes
ould lead to worsening cardiac dysfunction over time. Measuring cTn may help to clarify
he mechanism of worsening HF, improve risk stratification, and aid in the early detection of
armful side effects of new therapies.ARLY PHASE CLINICAL TRIALS1079sPLA Inhibitor Reduces Inflammatory Biomarkers in Post-ACS Subjects2
obert S. Rosenson, Colin Hislop, Michael Elliott, Yuri Stasiv, Michael Goulder, David Waters
arespladib, a selective secretory phospholipase A2 (sPLA2) inhibitor, has been shown to
ower levels of sPLA2-IIA by more than 90%, low-density lipoprotein cholesterol (LDL-C)
y 12% to 18%, and high-sensitivity C-reactive protein (hsCRP) by 20% to 40% in stable
oronary heart disease patients. This randomized controlled trial investigated the effects of
PLA2 inhibition with varespladib as adjunctive therapy to atorvastatin in patients with recent
cute coronary syndrome (ACS). After 8 weeks, varespladib/atorvastatin reduced mean
DL-C levels from baseline by 50% compared to 43% with placebo/atorvastatin, with
eductions in sPLA2-IIA levels of 82% and 16%, and nonsignificant differences in
sCRP reductions. The rate of major adverse cardiovascular events was not different from
lacebo after 6 months in the small trial, and there were no safety problems identified.
arespladib safely reduces LDL-C and sPLA2-IIA in post-ACS patients, but larger
tudies are needed to determine its effect on outcomes.(continued on page A-20)
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aARLY PHASE CLINICAL TRIALS1089Implanted Monitor Can Detect Coronary Ischemiaim A. Fischell, David R. Fischell, Alvaro Avezum, M. Sasha John, David Holmes, Malcolm Foster III,
ichard Kovach, Paulo Medeiros, Leopoldo Piegas, Helio Guimaraes, C. Michael Gibson
ischell and colleagues report the first clinical studies of intracardiac ST-segment monitoring
n ambulatory humans to detect coronary ischemia. The device uses a modified lead
mplanted into the right ventricular apex, which is implanted in a manner similar to a
acemaker. It is programmed to the patient’s baseline levels of ischemia. For ST-segment
hanges beyond the thresholds, the device emits an audible alarm. During follow-up of 37
ubjects, 4 developed ST-segment shifts 3 SDs of their normal daily range. This prompted
mergent evaluations that confirmed coronary occlusion or ruptured plaque, with a median
larm-to-door time of 19.5 min. The device also detected progressive atherosclerosis in the
orm of demand-related ischemia in 4 other subjects.ARDIAC INTERVENTION AND SURGERY1099Meta-Analysis Confirms Benefit of Pre-Procedural Statin Therapyavid E. Winchester, Xuerong Wen, Lola Xie, Anthony A. Bavry
inchester and colleagues performed a meta-analysis of trials that randomized subjects to
tatins prior to percutaneous coronary intervention (PCI), coronary artery bypass grafting
CABG), or noncardiac surgery. Pre-procedural statins significantly reduced post-procedural
yocardial infarction (MI) (risk ratio [RR]: 0.57) in the almost 5,000 subjects. This benefit
as seen after both PCI and noncardiac surgical procedures, but not after CABG. All-cause
ortality was nonsignificantly reduced from statin therapy (RR: 0.66, p  0.15). Pre-
rocedural statins also reduced post-CABG atrial fibrillation. Statins administered before
nvasive procedures significantly reduce the risk of post-procedural MI, with favorable trends
or mortality.ditorial Comment: Kim A. Eagle, Vineet Chopra, p. 1110ETABOLIC SYNDROME1113Meta-Analysis Confirms Increased Risk in Patients With Metabolic Syndromealvatore Mottillo, Kristian B. Filion, Jacques Genest, Lawrence Joseph, Louise Pilote, Paul Poirier,
téphane Rinfret, Ernesto L. Schiffrin, Mark J. Eisenberg
ottillo and colleagues conducted a systematic review and meta-analysis of the cardiovascular
isk associated with the metabolic syndrome as defined by the 2001 National Cholesterol
ducation Program and the 2004 revised National Cholesterol Education Program
efinitions. A total of 87 studies were identified, which included almost 1 million subjects.
he metabolic syndrome was associated with an approximate doubling in the risk of each of
he following end points: cardiovascular disease (CVD), CVD mortality, all-cause mortality,
yocardial infarction, and stroke. These results confirm that the metabolic syndrome is
ssociated with increased cardiovascular risk.(continued on page A-22)
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sEART RHYTHM DISORDERS1133Fewer Procedural Complications in Hospitals That Implant More ICDsames V. Freeman, Yongfei Wang, Jeptha P. Curtis, Paul A. Heidenreich, Mark A. Hlatky
reeman and colleagues examined the relationship between hospital implantable cardioverter-
efibrillator (ICD) implantation volume and procedural complications using data from the
ational Cardiovascular Data Registry ICD Registry. The rate of adverse events declined
rogressively with increasing procedure volume and remained significant after adjustment for
atient clinical, operator, and hospital characteristics. Patients who have an ICD implanted at
high-volume hospital are less likely to have an adverse event associated with the procedure
han patients who have an ICD implanted at a low-volume hospital.EART FAILURE1140Physical Activity Linked to Decreased Risk of HFujie Wang, Jaakko Tuomilehto, Pekka Jousilahti, Riitta Antikainen, Markku Mähönen,
eter T. Katzmarzyk, Gang Hu
ang and colleagues studied whether occupational, commuting, or leisure-time physical
ctivity reduced the risk of heart failure (HF). Nearly 60,000 Finnish men and women were
sked about different kinds of physical activity along with other potential predictors of HF
nd were then followed for a mean of 18 years. After adjustment, active occupational activity
educed the risk of HF by 10% to 20%, with stronger reductions for high leisure-time
hysical activity. There were further reductions when subjects were active in more than one
omain. Moderate and high levels of physical activity may reduce the risk of HF.CONGENITAL HEART DISEASE ONGENITAL HEART DISEASE1149Decreasing Childhood Deaths in Patients With Congenital Heart Diseaseaul Khairy, Raluca Ionescu-Ittu, Andrew S. Mackie, Michal Abrahamowicz, Louise Pilote, Ariane J. Marelli
hairy and colleagues performed a population-based cohort study of patients with congenital
eart disease (CHD) to determine if recent advances have altered rates of mortality. Between
987 and 2005, almost 72,000 people were identified as having CHD and were followed for
early 1 million patient-years. The proportion of infant and childhood deaths markedly
eclined from 1987 to 2005. Mortality rates decreased in all age groups below 65 years, with
he largest reduction in infants (mortality rate ratio: 0.23). Deaths in patients with CHD have
hifted away from infants toward adults, with a steady increase in age at death.
